Physician profile
Neama Esmaili
NPI 1568665628
$1,388.68
in general payments reported to CMS, 2019-2025
22 companies · $19.36 in 2025
The $19.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $680 · 2021: $23.63 · 2025: $19.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.12 | 2019-2020 | |
| Novo Nordisk INC | $132.60 | 2019-2020 | |
| Pfizer INC. | $101.22 | 2019 | |
| Amarin Pharma, INC. | $92.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.09 | 2019-2020 | |
| Allergan, INC. | $72.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $63.82 | 2019-2020 | |
| Astellas Pharma US INC | $62.18 | 2019-2020 | |
| Amgen INC. | $56.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.21 | 2019-2025 | |
| Lilly USA, LLC | $43.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $42.76 | 2020 | |
| Daiichi Sankyo INC. | $42.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.55 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $31.29 | 2020 | |
| Antares Pharma, INC. | $27.15 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.36 | 2019 | |
| Abbvie INC. | $23.63 | 2021 | |
| Boston Scientific Corporation | $14.00 | 2019 | |
| Sanofi Pasteur INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neama Esmaili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.